Metformin Reduce the Relapse Rate on Patients With B-cell Precursor (Ph+ Negative) Acute Lymphoblastic Leukemia
Status:
Completed
Trial end date:
2017-04-30
Target enrollment:
Participant gender:
Summary
Metformin's Antitumor activity were identified from differens diabetic patients trials,
mainly associated to its mechanism of action and protein - kinase AMPK (AMP-activated protein
kinase) activation. According to Cancer and Diabetes International Consensus from 2012,
diabetes increases the risk for developping cancer and metformin has an protector effect
against cancer cells and has an impact on overall survival.
Chemotherapy drug resistance induces treatment fail in oncology. Metformin increases AMPK
levels, blocks PI3K (phosphatidylinositol 3- kinase)/ AKT /mTOR(mammailian Target of
Rapamycin) pathway but few evidence associated with drug resistance gene expression.
This is an, experimental one-center study that pretends to stablish the effect of adding
metformin 850 mg PO three times a day over the multi-drug resistance gene expression (ABCB1)
in de novo Acute Lymphoblastic Leukemia in one 7-days cycle with prednisone as pre-treatment-
and on the induction remission treatment.